Brief: Alzamend Neuro Submits Ind Application For Phase Iia Clinical Trial Of Al001
30/08/2023 13:11
Aug 30 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO SUBMITS IND APPLICATION FOR PHASE IIA
CLINICAL
TRIAL OF AL001, A NEXT-GENERATION LITHIUM THERAPEUTIC DRUG
CANDIDATE, IN BIPOLAR DISORDER PATIENTS
* ALZAMEND NEURO INC - SAFETY ASPECTS OF AL001 DEVELOPMENT
MAY
QUALIFY FOR (505)(B)(2) PATHWAY FOR FDA APPROVAL
Source text for Eikon: ID:nBw1z0gZsa
Further company coverage: ALZN.O
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview